Association between HLA-A gene polymorphism and early-onset preeclampsia in Chinese pregnant women early-onset

Yuanyuan Zheng, Cui Ma, Xiaowei Liu, Shaowen Wu, Weiyuan Zhang* and Shenglong Zhao

Abstract

Background: Preeclampsia is an idiopathic disease during pregnancy. This study explores the correlation between HLA-A polymorphism and the onset of preeclampsia.

Methods: The Illumina HiSeq2500 sequencing platform was used to genotyping HLA-A allele in venous blood DNA of 50 preeclampsia pregnant women and 48 normal pregnant women and umbilical cord blood DNA of their children of Han nationality in China. The frequencies and distributions of alleles and genotypes among the mothers and their children were compared between the two groups. The differences of frequencies and distributions of genotypes were compared between the two groups according to the mothers’ genotype compatibility.

Results: Twenty HLA-A alleles were detected in preeclampsia pregnant women and normal pregnant women; 21 HLA-A alleles were found in preeclampsia group fetuses and 22 HLA-A alleles in control group fetuses. There was no statistical difference in the HLA-A genes’ frequency between the two groups of pregnant women and their fetuses. When the sharing antigen was 1, the number of maternal-fetal pairs in the preeclampsia group was more than that in the control group; the difference was statistically significant ($P < 0.05$). The frequency of neither mother nor fetus carrying the HLA-A *24:02 gene in the preeclampsia group was significantly lower than that in the control group ($P < 0.05$). HLA-A gene homozygosity in fetuses of early-onset preeclampsia group was substantially higher than that of the control group ($P = 0.0148$); there is no significant difference in pregnant women’s genes homozygosity between early-onset preeclampsia group and the control group.

Conclusions: HLA-A *24:02 may be a susceptibility gene for early preeclampsia.

Keywords: Human leukocyte antigen, Preeclampsia, HLA-A polymorphism
Background
Preeclampsia is an idiopathic disease during pregnancy. The clinical manifestations of preeclampsia are hypertension and/or proteinuria after 20 weeks of pregnancy, accompanied by systemic organ function damage and placenta function damage, which seriously endangers mothers and children [1]. It is the leading cause of maternal death and an essential reason for increasing perinatal incidence and mortality. The prevalence of preeclampsia is approximately 1.5–4.6% in the whole world [2]. According to the difference in onset gestational age, pathogenesis, and pathologic characteristics, the preeclampsia can be divided into early-onset preeclampsia and late onset preeclampsia [3]. Early-onset preeclampsia is characterized by early-onset, rapid disease progression, numerous maternal and infant complications, and high maternal and child mortality. The pathogenesis of early-onset preeclampsia has not been cleared yet, the characteristic pathology of early-onset preeclampsia turns into uterine spiral artery remodeling disorder, shallow placenta implantation, and the arterial pathology of the placental bed in patients became similar to acute transplant rejection, which are summarized in placental disease [4].

Human leukocyte antigen (HLA) plays a leading role in the immune function and participates in the rejection of transplantation. HLA-A belongs to the typical HLA class I-a antigen[4]. It recognizes and presents endogenous antigens, triggers allogeneic rejection, and has a high degree of genetic polymorphism. This study explores the relationship between HLA-A polymorphism and the early-onset preeclampsia, and lays the foundation for further elucidating the pathogenesis of early-onset preeclampsia.

Methods
Research subjects
A total of 98 pregnant women delivered in Beijing Maternity Hospital from October 2017 to October 2019 were included in our present study. 50 cases of early-onset preeclampsia women with gestational age ≤34 weeks were selected as the experimental group, and 48 cases of normal pregnant women who delivered at the same time were selected as the control group. The average age of preeclampsia pregnant women was 30.60 ± 5.76 years old, and the average pregnancy was 31.95 ± 2.22 weeks. The average pregnancy was 30.60 ± 5.76 years old, and the average pregnancy was 31.95 ± 2.22 weeks. The average pregnancy was 31.95 ± 2.22 weeks. The average pregnancy was 31.95 ± 2.22 weeks. The average pregnancy was 31.95 ± 2.22 weeks.

According to the Guidelines for the Diagnosis and Treatment of Hypertensive Diseases During Pregnancy (2015), the diagnostic criteria for preeclampsia were blood pressure rises after 20 weeks of pregnancy, systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, accompanied by any of the following: proteinuria ≥0.3 g/24 h, or proteinuria / creatinine ratio ≥0.3, or random proteinuria ≥(+); no proteinuria but with the involvement of any of the following organs (heart, lung, liver, kidney and other vital organs) or systems (hematological system, digestive system, nervous system), placenta fetus involvement, etc. All subjects and their families signed informed consent.

Statistics analysis
Plink statistical software was used to analyze the gene frequency. The allele and genotype frequencies of each test site were calculated, and the Hardy-Weinberg
equilibrium was verified [5]. Pearson’s chi-squared test or Chi-square test of continuity correction or Fisher exact probability method was used to calculating the gene frequency difference between the two groups. A $P < 0.05$ represents significant statistical difference.

Results
Distribution of HLA-A alleles in early-onset preeclampsia pregnant women and normal pregnant women
20 HLA-A alleles were detected in 50 cases of early-onset preeclampsia pregnant women in the experimental group. The alleles accounting for more than 10% were HLA-A*24:02 (20%), -A*02:01 (15%), -A*11:01 (12%), dominant alleles were not found. 20 HLA-A alleles were detected in 48 pregnant women in the control group. The alleles accounting for more than 10% were HLA-A*02:01 (15%), -A*11:01 (14%), -A*02:06 (10%), dominant alleles were not found. The proportion of HLA-A*24:02 (20%) genes in early-onset preeclampsia pregnant women was significantly higher than that of normal pregnant women (9.38%), but the difference didn’t have statistically significant. See Table 1 for details.

Distribution of HLA-A alleles in early-onset preeclampsia group fetuses and normal group fetuses
21 HLA-A alleles were detected in 50 cases of early-onset preeclampsia group fetuses. The alleles accounting for more than 10% were HLA-A*02:01 (20%), -A*24:02 (19%), -A*11:01 (14%), dominant alleles were not found. 22 HLA-A alleles were detected in 48 fetuses in the control group. The alleles accounting for more than 10% were HLA-A*11:01 (17.71%), -A*02:01 (15.62%), -A*24:02 (12.5%), dominant alleles were not found. The proportion of HLA-A*24:02 (19%) genes in early-onset preeclampsia group fetus were significantly higher than that in the control group fetus (12.5%), but the difference didn’t have statistically significant. See Table 2 for details.

Comparison of HLA-A antigen sharing frequency between mother and fetus in early-onset preeclampsia and control group
The HLA gene is a multiple alleles; there are two antigenic phenotypes in each HLA locus on a homologous chromosome pair. One-half of the fetal genes are from the mother, and the other half is from the father, so there must be 1 or 2 identical HLA-A phenotypes between the mother and the fetus. If there is one identical antigens between the mother and fetus, the number of shared antigens is recorded as 1. If there are two identical antigens between the mother and fetus, the number of shared antigens is recorded as 2.

There were five pairs of mothers and fetuses having two shared antigens in the preeclampsia group, accounting for 10% (5/50). There were 44 pairs of mothers and fetuses having one shared antigen in the preeclampsia group, accounting for 88% (44/50). There were 13 pairs of mothers and fetuses having 2 shared antigens in the preeclampsia group, accounting for 27.08% (13/48). There were 35 pairs of mothers and fetuses having 1 shared antigen in the preeclampsia group, accounting for 72.92% (35/48). The difference was statistically significant ($P < 0.05$). See Table 3 for details.

Analysis of the compatibility frequency of HLA-A alleles between mothers and fetuses in early-onset preeclampsia group and control group
The higher allele frequency (> 10%) (HLA-A*11:01, -A*02:01, -A*24:02) in early-onset preeclampsia group and control group were selected to analyze these genes compatibility between mother and child. The results showed that the frequency of neither mother nor fetus carrying

---

**Table 1** Comparison of HLA-A allele frequency distribution among mothers in preeclampsia group and control group

| Gene | Alleles | Control Group | Preeclampsia Group |
|------|---------|---------------|--------------------|
| **A** | A*01:01 | 5 (5.21%) | 3 (3.00%) |
|      | A*01:22 | 0 (0.00%) | 2 (2.00%) |
|      | A*02:01 | 15 (15.62%) | 15 (15.00%) |
|      | A*02:03 | 1 (1.04%) | 2 (2.00%) |
|      | A*02:05 | 1 (1.04%) | 2 (2.00%) |
|      | A*02:06 | 10 (10.42%) | 9 (9.00%) |
|      | A*02:07 | 8 (8.33%) | 5 (5.00%) |
|      | A*02:10 | 1 (1.04%) | 1 (1.00%) |
|      | A*02:17 | 0 (0.00%) | 0 (0.00%) |
|      | A*02:48 | 1 (1.04%) | 0 (0.00%) |
|      | A*03:01 | 3 (3.12%) | 6 (6.00%) |
|      | A*03:02 | 1 (1.04%) | 1 (1.00%) |
|      | A*11:01 | 14 (14.58%) | 12 (12.00%) |
|      | A*11:02 | 1 (1.04%) | 0 (0.00%) |
|      | A*24:02 | 9 (9.38%) | 20 (20.00%) |
|      | A*24:03 | 0 (0.00%) | 0 (0.00%) |
|      | A*24:20 | 0 (0.00%) | 0 (0.00%) |
|      | A*26:01 | 4 (4.17%) | 1 (1.00%) |
|      | A*29:01 | 1 (1.04%) | 1 (1.00%) |
|      | A*30:01 | 9 (9.38%) | 6 (6.00%) |
|      | A*31:01 | 5 (5.21%) | 5 (5.00%) |
|      | A*32:01 | 4 (4.17%) | 1 (1.00%) |
|      | A*33:03 | 2 (2.08%) | 6 (6.00%) |
|      | A*34:01 | 0 (0.00%) | 1 (1.00%) |
|      | A*66:01 | 0 (0.00%) | 0 (0.00%) |
|      | A*68:01 | 1 (1.04%) | 1 (1.00%) |
| **A(Total)** | 96 (100.00%) | 100 (100.00%) |
the HLA-A*24:02 gene in the preeclampsia group was significantly lower than that in the control group ($P < 0.05$). See Table 4 for details.

**Comparison of HLA-A allele homozygosity between mother and fetus in early-onset preeclampsia group and control group**

When two alleles at the same locus of a homologous chromosome are not the same, they are heterozygous. When two alleles at the same locus of a homologous chromosome are not the same, they are heterozygous. The results showed that the HLA-A gene homozygosity in fetuses of the early-onset preeclampsia group was significantly higher than that of the control group ($P = 0.0148$).

There is no significant difference in pregnant women's gene homozygosity between the early-onset preeclampsia and the control groups. See Table 5 for details.

**Discussion**

The children carry half of the HLA genes from their mothers and a half from their fathers [6]. During pregnancy, the fetus carrying the paternal HLA gene will be regarded as a homograft. Under normal circumstances, the pregnancy can continue smoothly because of the immune tolerance between mother and fetus. Once the immune tolerance balance is broken, immune abnormalities occur at the maternal-fetal interface, which leads to the reduced invasive capacity of placental trophoblasts, recast dysfunction of the spiral uterine artery, damage to the vascular endothelium, the release of inflammatory factors [7]. These changes were similar to transplant rejection reactions. The fetus will be treated as allogeneic. Simultaneously, the mother has hypertension, proteinuria, impaired organ function, fetus' growth retardation, and low body weight [8].

Aa classic HLA-I antigen, HLA-A is distributed on the surface of almost all nucleated cells in the body. Its primary function is to present endogenous antigens to CD8+ T lymphocytes to participate in specific immune responses and the genetic regulation of immune responses. Many scholars have studied the HLA-A and preeclampsia, but the results were not the same [9]. Biggar [10] found that HLA-A gene sharing and distribution frequency between mothers and fetuses were not significantly different in the preeclampsia group than normal pregnant women. However, Triche et al. [11] analyzed the relationship between pregnant women in the preeclampsia group and the semen exposure time, and found that the effect of HLA-A gene sharing between mothers and fetuses in preeclampsia pregnant women in the low semen exposure group increased significantly (OR = 6.27, 95% CI is 1.04, 37.99). Emmery et al. [12] found no significant correlation in HLA-A gene sharing between preeclampsia maternal and fetal after correcting the body mass index and smoking factors.

**Table 2** Comparison of HLA-A allele frequency distribution in fetuses in preeclampsia group and control group

| Gene | Alleles | Control Group | Preeclampsia Group |
|------|---------|---------------|-------------------|
| A    | A*0101  | 3(3.12%)      | 3(3.00%)          |
|      | A*0122N | 2(2.08%)      | 1(1.00%)          |
|      | A*0201  | 15(15.62%)    | 20(20.00%)        |
|      | A*0203  | 0(0.00%)      | 0(0.00%)          |
|      | A*0205  | 2(2.08%)      | 2(2.00%)          |
|      | A*0206  | 8(8.33%)      | 5(5.00%)          |
|      | A*0207  | 5(5.21%)      | 6(6.00%)          |
|      | A*0210  | 1(1.04%)      | 1(1.00%)          |
|      | A*0217  | 1(1.04%)      | 0(0.00%)          |
|      | A*0248  | 1(1.04%)      | 0(0.00%)          |
|      | A*0301  | 3(3.12%)      | 4(4.00%)          |
|      | A*0302  | 1(1.04%)      | 1(1.00%)          |
|      | A*1101  | 17(17.71%)    | 14(14.00%)        |
|      | A*1102  | 2(2.08%)      | 1(1.00%)          |
|      | A*2402  | 12(12.50%)    | 19(19.00%)        |
|      | A*2403  | 1(1.04%)      | 0(0.00%)          |
|      | A*2420  | 0(0.00%)      | 1(1.00%)          |
|      | A*2601  | 2(2.08%)      | 2(2.00%)          |
|      | A*2901  | 1(1.04%)      | 1(1.00%)          |
|      | A*3001  | 8(8.33%)      | 8(8.00%)          |
|      | A*3101  | 3(3.12%)      | 5(5.00%)          |
|      | A*3201  | 3(3.12%)      | 2(2.00%)          |
|      | A*3303  | 4(4.17%)      | 2(2.00%)          |
|      | A*3401  | 0(0.00%)      | 0(0.00%)          |
|      | A*6601  | 0(0.00%)      | 1(1.00%)          |
|      | A*6801  | 1(1.04%)      | 1(1.00%)          |
| A(Total)| 96(100.00%) | 100(100.00%) |
the homozygous rate of HLA-A gene loci in preeclampsia pregnant women was the corresponding rise.

There are several findings in our research. (1) There was no significant difference in the distribution of HLA-A gene frequency between the preeclampsia and control groups. The results were similar to those of Zhang et al. In their study on the association between preeclampsia HLA-A gene polymorphism and preeclampsia, there was no significant difference in HLA-A allele between preeclampsia group and control group \( (P < 0.05) \) [13]. But we still observed that the frequency of HLA-A *24:02 gene in pregnant women and fetuses in the preeclampsia group is about 10% higher than that in the control group. Moreover, the number of neither mother nor fetus not carrying this gene in the healthy pregnancy group was higher than that in the early-onset preeclampsia group. Whether HLA-A * 24: 02 is a preeclampsia susceptibility gene needs to expand the sample for further research. (2) In the HLA-A gene sharing between mother and fetus, the gene sharing between mother and fetus in the control group \( (OR = 0.31, 95\% CI = 0.10, 0.94) \) was more than that in early-onset preeclampsia group, which suggests that the HLA-A gene sharing between mother and fetus is conducive to the maternal and fetal immune tolerance of pregnancy and protect the fetus from maternal rejection. Robert J et al. analyzed 201 pairs of maternal-infant HLA-A and found that maladaptation mediated by adaptive immunity between mother and infant was not based on maternal development of preeclampsia/eclampsia [14]. This view is also found in a questionnaire survey on the relationship between donors in donor pregnancy [13]. Compared with family-related donors, when donors were not related to recipients, hypertension incidence during pregnancy has increased. It is also suggested that HLA histocompatibility between the mother and fetus was beneficial to a healthy pregnancy. (3) Fetal HLA-A homozygosity was associated with preeclampsia. The results are consistent with those of Redman et al [15]. The possible reason is that the mother will have an immune tolerance response after contacting the HLA antigen of the sexual partner’s semen, but the HLA homozygote of the fetus will reduce the heterogeneity of the antigen between couples, reduce the mother’s immune tolerance formation and weaken immune protection, thereby inducing the occurrence of preeclampsia. (4) The father plays an important role in the onset of preeclampsia. Pregnancy can be regarded as a successful semi-allograft. As a half-barrel allograft, the fetus evades the immune attack of the mother, which plays a very important role in the immune recognition of HLA antigens expressed by fetal cells from the paternal side [16]. Some specific gene compatibility patterns between couples may be related to the onset of preeclampsia. Paternal genes may result in immune disorders between mother and fetus, immune intolerance, and rejection of the fetus, which by insufficient blocking antibodies caused by antigen

---

**Table 4** Compatibility frequency of some alleles carried by mother and fetus in preeclampsia group and control group

| Maternal / Fetal Genes | Maternal genotype / fetal genotype | Preeclampsia Group | Control Group | OR(CI) | P-value |
|------------------------|-----------------------------------|--------------------|---------------|--------|---------|
| A*24:02                | --                                | 27                 | 36            | 0.39(0.17,0.92) | 0.0363  |
| A*24:02                | +                                 | 7                  | 1             | 7.65(0.90,64.75) | 0.0597  |
| A*24:02                | ++                                | 11                 | 6             | 1.97(0.67,5.85)  | 0.288   |
| A*24:02                | -                                 | 5                  | 5             | 0.96(0.26,3.53)  | 1.00    |
| A*11:01                | ++                                | 6                  | 8             | 0.68(0.22,2.14)  | 0.573   |
| A*11:01                | --                                | 31                 | 28            | 1.17(0.52,2.62)  | 0.837   |
| A*11:01                | +                                 | 5                  | 4             | 1.22(0.31,4.85)  | 1.00    |
| A*11:01                | -                                 | 8                  | 8             | 0.95(0.33,2.78)  | 1.00    |
| A*02:01                | +                                 | 2                  | 5             | 0.36(0.07,1.94)  | 0.264   |
| A*02:01                | --                                | 34                 | 28            | 1.52(0.66,3.47)  | 0.403   |
| A*02:01                | +                                 | 9                  | 10            | 0.83(0.31,2.27)  | 0.801   |
| A*02:01                | -                                 | 5                  | 5             | 0.96(0.26,3.53)  | 1.00    |

---

**Table 5** HLA homozygous / heterozygous distribution of mother and fetus

| Gene   | Neonate Control Group | Preeclampsia Group | P     | Pregnant Woman Control Group | Preeclampsia Group | P     |
|--------|-----------------------|--------------------|-------|-----------------------------|--------------------|-------|
|        | 48(100.00%)           | 50(100.00%)        |       | 48(100.00%)                 | 50(100.00%)        |       |
| Homozygous | 2(4.17%)            | 11(22.00%)         | 0.0148| 4(8.33%)                    | 7(14.00%)          | 0.525 |
| Heterozygous | 46(95.83%)         | 39(78.00%)         |       | 44(91.67%)                  | 43(86.00%)         |       |
sharing between couples, and too few protective antibodies produced by the mother; it may also be through susceptible genes, and immunological dysfunction caused by gene linkage imbalance leads to preeclampsia. The specific mechanism needs to explored from expanding the sample size and the whole family in the future. Due to the limitation of the number of cases in this study, the relationship between paternal HLA-A allele and the sharing of HLA-A gene between couples and preeclampsia needs to be expanded and further study.

Conclusions
In conclusion, HLA-A * 24:02 may be a susceptibility gene for early preeclampsia. This gene may have a greater impact on the occurrence and development of early preeclampsia. Therefore, more detailed research of this gene are of great significance for the prevention of early preeclampsia.

Abbreviation
HLA: Human leukocyte antigen

Acknowledgements
None.

Authors’ contributions
YZ, CM and WZ designed the study. YZ, CMXL and SW collected and analyzed the data. JZ and CM drafted and wrote the manuscript. WZ and SZ revised the manuscript critically for intellectual content. The authors gave intellectual input to the study and approved the final version of the manuscript.

Funding
This study was supported by National Key Research and Development Program of China (2016YFC1000403). The funders had no role in research design, data collection, data analysis, or preparation of the manuscript for publication.

Ethics approval and consent to participate
The study protocol was approved by the Institutional Review Board of Beijing Obstetrics and Gynecology Hospital. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from every participant.

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 1 April 2020 Accepted: 15 October 2020
Published online: 30 October 2020

References
1. Obstetricians, ACo. Gynecologists, Pregnancy TFOHi: Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–1131.
2. Mayrink J, Costa ML, Cecatti JG. Preeclampsia in 2018: revisiting concepts, pathophysiology, and prediction. Scientific World Journal. 2018;2018:1–9.
3. Valenise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension. 2008;52(5):873–880.
4. Corporation HP. The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol. 2010;2010(1):103–105.
5. Li YD, Ji YT, Zhou XH, Li HL, Zhang HT, Xing Q, Hong YF, Tang BP. TNNT2 gene polymorphisms are associated with susceptibility to idiopathic dilated cardiomyopathy in Kazak and Han Chinese. Med Sci Monit Int Med J Exper Clin Res. 2015;21:3343–3347.
6. Zhang J, Patel G. Partner change and perinatal outcomes: a systematic review. Paediatric Perinatal Epidemiology. 2007;21(1):46–57.
7. Pfeifer C, Bunders MJ. Maternal HIV infection alters the immune balance in the mother and fetus; Implications for pregnancy outcome and infant health. Curr Opin HIV AIDS. 2015;11(2):138–45.
8. Brosens I, Dixon HG, Robertson WB. Fetal growth retardation and the arteries of the placental bed. BJOG An Int J Obstet Gynaecol 1977;84:65-66.
9. Kilpatrick DC, Liston WA, Gibson F, Livingstone J. Association between susceptibility to pre-eclampsia within families and HLA DR4. International Journal of Gynecology Obstetrics. 1989;2(8671):1063–5.
10. Biggar RJ, Poulsen G, Ng J, Melbye M, Boyd HA. HLA antigen sharing between mother and fetus as a risk factor for eclampsia and preeclampsia. Hum Immunol 2010;71(3):267.
11. Triche EW, Harland KK, Field EH, Rubenstein LM, Saftlas AF. Maternal-fetal HLA sharing and preeclampsia: variation in effects by seminal fluid exposure in a case–control study of nulliparous women in Iowa. J Reprod Immunol 2014;101:101–111–119.
12. Emmery J, Hackmon R, Pyo CW, Nelson WC, Geraghty DE, Andersen AMN, Melbye M, Hvid TVF. Maternal and fetal human leukocyte antigen class Ia and II alleles in severe preeclampsia and eclipmsia. Genes Immun. 2016;17:251-60.
13. Lashley LEO, Haasnoot GW, Spruyt-Genitse M, Clas FHJ. Selective advantage of HLA matching in successful uncomplicated oocyte donation pregnancies. J Reprod Immunol. 2015;112:29–33.
14. Biggar RJ, Poulsen G, Ng J, Melbye M, Boyd HA. HLA antigen sharing between mother and fetus as a risk factor for eclampsia and preeclampsia. Hum Immunol 2010;71(3):267–269.
15. Redman CW, Bodmer JG, Bodmer WF, Bellin LJ, Bonnar J. HLA antigens in severe pre-eclampsia. Lancet 1978;2(8671):397-9.
16. Beydoun H, Saftlas AF. Association of human leucocyte antigen sharing with recurrent spontaneous abortions. Tissue Antigens. 2005;62(2):123–35.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.